Document is current
Any future updates will be listed below
-
Authors
Thomas, T.
Casado, E.
Geusens, P.
Lems, W. F.
Timoshanko, J.
Taylor, D.
Hofbauer, L. C.
-
Funding
Funding for this research was provided by:
UCB Pharma (Not applicable)
Amgen Inc. (Not applicable)
- License Information
-
More Information
Article History
Received: 13 December 2019
Accepted: 24 July 2020
First Online: 7 August 2020
Compliance with ethical standards
:
: None.
: TT: consultant/speaker for AbbVie, Amgen Inc., Arrow, Biogen, Bristol-Myers Squibb, Chugai, Expanscience, Gilead, Grunenthal, HAC Pharma, LCA, Lilly, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Thuasne, Teva and UCB Pharma; received financial support or fees for research activities from Amgen Inc., Bone Therapeutics, Chugai, HAC Pharma, Merck Sharp & Dohme, Novartis, Pfizer and UCB Pharma; EC: speaker for Amgen Inc., Lilly and Rubió; received advisory board honoraria from Stada, Theramex and UCB Pharma; PG: received advisory board honoraria from UCB Pharma; WL: received advisory board honoraria from Amgen Inc., Eli Lilly and UCB Pharma; JT: employed by and stockholder of UCB Pharma; DT: employed by Ogilvy Health at the time of the study and funded by UCB Pharma and Amgen Inc. to conduct this study; LCH: received advisory board honoraria from Alexion, Amgen Inc., Kyowa Kirin International, Shire and UCB Pharma.
